146 related articles for article (PubMed ID: 26429715)
1. Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development.
Quynh Doan NT; Christensen SB
Curr Pharm Des; 2015; 21(38):5501-17. PubMed ID: 26429715
[TBL] [Abstract][Full Text] [Related]
2. Targeting thapsigargin towards tumors.
Doan NT; Paulsen ES; Sehgal P; Møller JV; Nissen P; Denmeade SR; Isaacs JT; Dionne CA; Christensen SB
Steroids; 2015 May; 97():2-7. PubMed ID: 25065587
[TBL] [Abstract][Full Text] [Related]
3. From Plant to Patient: Thapsigargin, a Tool for Understanding Natural Product Chemistry, Total Syntheses, Biosynthesis, Taxonomy, ATPases, Cell Death, and Drug Development.
Christensen SB; Simonsen HT; Engedal N; Nissen P; Møller JV; Denmeade SR; Isaacs JT
Prog Chem Org Nat Prod; 2021; 115():59-114. PubMed ID: 33797641
[TBL] [Abstract][Full Text] [Related]
4. Thapsigargin--from Thapsia L. to mipsagargin.
Andersen TB; López CQ; Manczak T; Martinez K; Simonsen HT
Molecules; 2015 Apr; 20(4):6113-27. PubMed ID: 25856061
[TBL] [Abstract][Full Text] [Related]
5. Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
Janssen S; Jakobsen CM; Rosen DM; Ricklis RM; Reineke U; Christensen SB; Lilja H; Denmeade SR
Mol Cancer Ther; 2004 Nov; 3(11):1439-50. PubMed ID: 15542783
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
[TBL] [Abstract][Full Text] [Related]
7. Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics.
Isaacs JT; Brennen WN; Christensen SB; Denmeade SR
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946547
[TBL] [Abstract][Full Text] [Related]
8. Thapsigargin-From Traditional Medicine to Anticancer Drug.
Jaskulska A; Janecka AE; Gach-Janczak K
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374919
[TBL] [Abstract][Full Text] [Related]
9. Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells.
Christensen SB; Andersen A; Kromann H; Treiman M; Tombal B; Denmeade S; Isaacs JT
Bioorg Med Chem; 1999 Jul; 7(7):1273-80. PubMed ID: 10465403
[TBL] [Abstract][Full Text] [Related]
10. Targeted prodrug approaches for hormone refractory prostate cancer.
Aloysius H; Hu L
Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
[TBL] [Abstract][Full Text] [Related]
11. SERCA-inhibiting activity of C-19 terpenolides from Thapsia garganica and their possible biogenesis.
Appendino G; Prosperini S; Valdivia C; Ballero M; Colombano G; Billington RA; Genazzani AA; Sterner O
J Nat Prod; 2005 Aug; 68(8):1213-7. PubMed ID: 16124763
[TBL] [Abstract][Full Text] [Related]
12. Preparation of Enzyme-Activated Thapsigargin Prodrugs by Solid-Phase Synthesis.
Zimmermann T; Christensen SB; Franzyk H
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914143
[TBL] [Abstract][Full Text] [Related]
13. Design and total synthesis of unnatural analogues of the sub-nanomolar SERCA inhibitor thapsigargin.
Andrews SP; Tait MM; Ball M; Ley SV
Org Biomol Chem; 2007 May; 5(9):1427-36. PubMed ID: 17464412
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells.
Jakobsen CM; Denmeade SR; Isaacs JT; Gady A; Olsen CE; Christensen SB
J Med Chem; 2001 Dec; 44(26):4696-703. PubMed ID: 11741487
[TBL] [Abstract][Full Text] [Related]
15. Localization and in-Vivo Characterization of
Andersen TB; Martinez-Swatson KA; Rasmussen SA; Boughton BA; Jørgensen K; Andersen-Ranberg J; Nyberg N; Christensen SB; Simonsen HT
Plant Physiol; 2017 May; 174(1):56-72. PubMed ID: 28275147
[TBL] [Abstract][Full Text] [Related]
16. The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer.
Denmeade SR; Isaacs JT
Cancer Biol Ther; 2005 Jan; 4(1):14-22. PubMed ID: 15662118
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic phenylpropanoids and an additional thapsigargin analogue isolated from Thapsia garganica.
Liu H; Jensen KG; Tran LM; Chen M; Zhai L; Olsen CE; Søhoel H; Denmeade SR; Isaacs JT; Christensen SB
Phytochemistry; 2006 Dec; 67(24):2651-8. PubMed ID: 17098264
[TBL] [Abstract][Full Text] [Related]
18. A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells.
Christensen SB; Skytte DM; Denmeade SR; Dionne C; Møller JV; Nissen P; Isaacs JT
Anticancer Agents Med Chem; 2009 Mar; 9(3):276-94. PubMed ID: 19275521
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of a kunzeaol synthase from Thapsia garganica: implications for the biosynthesis of the pharmaceutical thapsigargin.
Pickel B; Drew DP; Manczak T; Weitzel C; Simonsen HT; Ro DK
Biochem J; 2012 Dec; 448(2):261-71. PubMed ID: 22938155
[TBL] [Abstract][Full Text] [Related]
20. Inhibitor of sarco-endoplasmic reticulum Ca2+-ATPase thapsigargin stimulates production of nitric oxide and secretion of interferon-gamma.
Kmonícková E; Melkusová P; Harmatha J; Vokác K; Farghali H; Zídek Z
Eur J Pharmacol; 2008 Jun; 588(1):85-92. PubMed ID: 18457829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
